Wednesday, November 25, 2020

Post Election Media on What's Next for $12 Billion California Stem Cell Program

Passage of Proposition 14 has generated a handful of articles recently dealing with the direction of the California stem cell agency over the next decade or so, including pieces carried by Bond Buyer and Calmatters, a respected online news service dealing with state government and politics.

Barbara Feder Ostrov wrote a Nov. 24 article for Calmatters, which quoted  Jonathan Thomas, chair of the California Institute for Regenerative Medicine (CIRM), as saying,
“California has always had a frontier mentality and a love for the cutting edge, and the work that CIRM has done has put it on the very forefront of regenerative medicine.”
Proposition 14 saved CIRM from financial extinction by requiring the state to borrow an additional $5.5 billion for the 16-year-old program, which was originally funded with $3 billion in state bonds in 2004. Total cost of the program is expected to hit about $12 billion before the money runs out again in 10 to 15 years.

Ostrov also quoted Paul Knoepfler, a UC Davis stem cell researcher and blogger, on new areas of research for CIRM that are authorized by Proposition 14. He said,
“Stem cells are interesting and important, but there are going to be a lot of new therapies in the next 10 years that are not stem-cell centric."
In the article, CIRM board member Ysabel Duron addressed the need for improvement of diversity in terms of developing therapies for underserved segments of the population. She said,
“We need to keep researchers’ feet to the fire. They need to show us a plan and we need to reward them.”
Ostrov quoted this writer on some of the issues facing CIRM, including the question of what happens when the latest $5.5 billion is exhausted:
“The sustainability issue is important and it’s hard to address.… The money doesn’t last forever.”
Bond Buyer's Keeley Webster's article noted that the agency will be rewriting its budget now that Proposition 14 has passed. The measure alters CIRM's budgeting rules, shifting some significant costs around. 

Webster quoted state Controller Betty Yee on the agency's $5 million Covid round from last spring. Yee said,
“The $5 million didn’t buy a lot, but it did help get information out to underserved communities. And it put a model out there of how CIRM has been able to accelerate research projects.”
In a piece by Andrew Sheeler, The Sacramento Bee quoted Robert Klein, a Palo real estate developer and sponsor of Proposition 14. Klein poured millions of dollars into the ballot campaign. He said, 
“We had a big obstacle because we had to communicate to voters not only the potential to change the nature of treatments ... but we also had to inform voters of how the state could afford this....It was a citizen’s initiative in the truest sense.”

Monday, November 23, 2020

California's Stem Cell Research Program: How $3 Billion is Growing to $12 Billion

California's 16-year-old stem cell research program is a prodigious enterprise that is helping to finance 68 clinical trials and that has funded hundreds of California scientists for their work in an embryonic field, so to speak. 

The scope and importance of the program and its cost, however, are not necessarily apparent to most Californians. The program is not high on the radar of most people and certainly not the subject of breakfast table conversations in the overwhelming majority of the state's households. 

Over the past 16 years, the California Stem Cell Report has regularly described the stem cell agency, known officially as the California Institute for Regenerative Medicine (CIRM), as a $3 billion effort. But the use of that number did not make it clear that the cost ran significantly higher. 

When CIRM was created through a ballot initiative in 2004, the state Legislative Analyst estimated it could cost taxpayers $6 billion because of the interest on the money that the state borrowed to finance it. The figure has turned out to be closer to $4 billion because of unusually low-interest rates over the last decade or so. 

Under Proposition 14, the agency will receive an additional $5.5 billion from state bonds to spend on research and other new programs. The state legislative analyst has estimated the total cost will run about $7.8 billion because of -- once again -- interest costs. 

The Proposition 14 funding brings the total estimated cost of CIRM to nearly $12 billion.  And that is the figure that the California Stem Cell Report will use going forward to describe the program, unless someone can convince this writer otherwise. 

Referring to CIRM as a $12 billion enterprise immediately tells the reader that it is a significant effort. The number helps to draw readers into stories about CIRM. It is also more accurate than using a smaller figure, which would tend to minimize the cost and mislead taxpayers. Describing CIRM only as a $8.5 billion ($3 billion plus $5.5 billion) agency tends to conceal its true cost to the people of California. (In retrospect, this website should have used the 2004, $6 billion figure to describe CIRM over the last 16 years.)

CIRM is a rare bird among state agencies for a number of reasons. In this case, we know that its funding will cease at some point. Nearly all state departments do not live with that sort of financial guillotine.  

The 17,000-word ballot initiative, crafted by Robert Klein, a Palo Alto real estate developer, limits CIRM's annual CIRM bond sales to $540 million. Based on the experience under the previous initiative -- Proposition 71 of 2004, which created CIRM -- the agency is not likely to hit the $540 million cap each year. That could extend CIRM's possible life for another 15 years or so unless it becomes unusually tight-fisted.

As for the $12 billion figure, this writer is open to arguments for using another number, but I will have to be convinced. I am prepared to air those arguments (their full text) on this website. So if a reader thinks another figure is more appropriate, please let me know the reasons why either by filing a comment using the comment function at the end of this item or by sending me an email at

Friday, November 20, 2020

Praise and Advice Given in Review of California's Stem Cell Research Program

The California stem cell agency today received both kudos and advice from the small state panel that is charged by law with reviewing its financial practices and is the only such state entity with that unique task. 

The panel is the Citizens Financial Accountability and Oversight Committee (CFAOC), which was created in 2004 as part of the ballot initiative that also created the California Institute for Regenerative Medicine (CIRM), as the agency is officially known. 

While it reviews the financial affairs of the agency, the CFAOC has no authority to require changes. CIRM's programs will cost state taxpayers an estimated $11.8 billion dollars before funds run out in 10 to 15 years. 

Betty Yee
Controller photo
State Controller Betty Yee is by law the chair of the CFAOC. It also has four other members, one of whom was sworn in just this morning. Yee and the others were liberal in their praise of the agency's work. In addition to the usual financial information, Maria Millan, CEO of the agency, presented the CIRM programs and their successes. 

Millan's presentation was greeted with praise by all the CFAOC members, including Yee. Towards the end of the meeting, Yee said that she and other members would like to be kept up-to-date regularly on CIRM matters since the CFAOC is required to meet only once a year. 

Yee said, "Numbers have lots of stories behind them. I think really to understand them fully, it is about exactly what we learned today."  She  said she hoped that part of the revision of CIRM's strategic plan next year will involve "how do we tell our story better."  Yee said she thought the agency was doing "great" but there was so much to be told. 

Catherine Sarkisian
UCLA photo

The new member of the CFAOC is Catherine Sarkisian, a UCLA physician who specializes in geriatric medicine, an area that Proposition 14 identified as a new target for CIRM.

Sarkisian raised a question about the need for diversity among recipients of  CIRM grants. CIRM officials pointed to existing training programs for high school and college students. Sarkisian said that those were important "pipelines" but that CIRM should consider creation of "on-ramps" to build up diversity among awardees. 

During the meeting, CIRM officials disclosed that the new strategic plan is expected to be approved next summer by the Independent Citizens Oversight Committee (ICOC), as the CIRM governing board is known. Work on it is already underway. Researchers and other members of the public can weigh in on what they would like to see funded over the next five years by emailing their comments to   

CIRM will be operating under a new, 17,000-word statute -- Proposition 14 -- that significantly expands the agency's scope and increases the ICOC size from 29 to 35. 

The new course of the agency is also likely to come up at a Dec. 21 meeting of the CIRM board. The public can address the board online or email comments. The agenda is legally required to be posted Dec. 11. It will contain instructions for online access to the meeting. 

Thursday, November 19, 2020

'Demeaning and Uncalled For:' A CIRM Complaint About the Use of the Word 'Obscure'

The California stem cell agency today sharply criticized an item on the California Stem Cell Report as "demeaning and uncalled for" because it described the four-person Citizens Financial Accountability and Oversight Committee (CFAOC) as "obscure."

The offending word was used in an article yesterday that previewed the first meeting of the committee in nearly 15 months. The CFAOC was created as part of the initiative that created the stem cell agency in 2004, which is known officially as the California Institute for Regenerative Medicine (CIRM)

The CFAOC reviews CIRM financial documents that have already been reviewed in public by CIRM's 29-member governing board, which is officially known as the Independent Citizen's Oversight Committee (ICOC). The CFAOC has no legal authority over CIRM beyond making possible recommendations.

The article in question began like this:

"One of the more obscure entities in state government is scheduled to meet this Friday to review the financial affairs of California's stem cell agency, a matter that now runs to nearly $12 billion.

"The panel is the Citizen's Financial Accountability Oversight Committee (CFAOC), which was created in 2004 along with the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is formally known. The CFAOC is charged with reviewing the financial practices of the stem cell agency. The CFAOC is the only state panel legally charged with that function. The governor and the legislature have no authority to do so."

Here is the text of the email expressing CIRM's displeasure with the use of the word "obscure." The email was written by Kevin McCormack, senior director of communication at CIRM.

"I think your characterization of the CFAOC in your latest column as 'One of the more obscure government entities' was demeaning and uncalled for. It may not have a high profile but it certainly has an important role. It was created by the voters in 2004 for a very specific purpose, to make sure we are held accountable, every year, for our financial performance. As one of the common, if erroneous, complaints about CIRM is that we are not accountable to the legislature or any other legislative body in Sacramento I would have thought the CFAOC should be praised not dismissed.


"This is a group of people who come together with the sole goal of making sure the state’s money is well spent. The members cover a broad range of professions but have one thing in common, they have vast experience in their area. They are appointed by the Controller, the Treasurer, the President pro Tempore of the Senate, and the Speaker of the Assembly (and one by CIRM). These are nobody’s fools, they are diligent in the way they work, meticulous in their analysis of how we work, and forceful in making recommendations. Which we then follow.


"At CIRM we are used to people criticizing us, more often than not incorrectly. The CFAOC deserves better."

As the author of the article in question, I have high regard for the CIRM staff and McCormack as well as the persons on the CFAOC. Nonetheless, it is an obscure state entitity, as are many state departments. More than 200 exist and most of them are obscure. Consider the State Allocation Board, for example, or the First 5 California

The count of 200 does not include state advisory bodies such as the CFAOC. If it did, the number would likely run into the thousands. Such bodies can do important work, such as was done by the Little Hoover Commission, an obscure state entity whose analysis and recommendations concerning CIRM won significant praise by the Institute of Medicine (IOM), which studied CIRM for months. 

What all these bodies have in common is that they are virtually unknown to the public, even to persons who consider themselves well-informed. 

The California Stem Cell Report writes about the CFAOC because of its connection to CIRM and the fact that both were created by the same 2004 initiative -- a measure criticized as ballot-box budgeting and that sometimes has also created impediments for CIRM. (See the IOM findings and recommendations.)

My bottom line? For a state body to be considered obscure is not a mark of shame. It is just a matter of fact.  

(Editor's note: A very early version of this item incorrectly said that Friday's meeting of the CFAOC will be the first in 19 months. The correct figure is 15 months.)


Wednesday, November 18, 2020

Financial Review of California's Multi-billion Dollar Stem Cell Research Agency Slated for Friday

One of the more obscure entities in state government is scheduled to meet this Friday to review the financial affairs of California's stem cell agency, a matter that now runs to nearly $12 billion.

The panel is the Citizen's Financial Accountability Oversight Committee (CFAOC), which was created in 2004 along with the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is formally known. The CFAOC is charged with reviewing the financial practices of the stem cell agency. The CFAOC is the only state panel legally charged with that function. The governor and the legislature have no authority to do so.

However, the CFAOC does not have authority to require changes by CIRM. It can only make recommendations.

Friday's agenda appears to be routine. However, some members of the committee may have comments on the approval of Proposition 14, which saved CIRM from financial extinction with $5.5 billion in money that the state will have to borrow.

Including Proposition 14, CIRM will cost taxpayers an estimated $11.8 billion by the time its funding runs out again in 10 to 15 years. Of that total, an estimated $3.3 billion will go for interest on the $8.5 billion in state funding for the agency, including the period since 2004. 

CIRM is likely to spend more than the $8.5 billion, however, because Proposition 14 provides for using private funds to hire additional personnel for the agency beyond a nominal cap of 70. CIRM has never had more than 62 employees and currently has about 33, two less than the 35 members of its governing board. 

On the CFAOC agenda are routine audits of the agency that have not identified any particular issues and presentations of previously reported budget plans. However, the meeting may include some discussion of CIRM's future, but don't look for a critical evaluation.

The last meeting of the CFAOC was in August 2019. State law requires an annual meeting. No meeting was held in 2018.

The chair of the panel is Betty Yee, the elected state controller. Other members include:
  • Jim Lott, a psychologist and former health care industry executive specializing in health care organizations and strategic thinking. 
  • Mark Fischer-Colbrie, CEO of Strateos,  Inc., of Menlo Park, Ca., and for chair of the international board of the Juvenile Diabetes Research Foundation, which is closely linked to Robert Klein, the sponsor of Proposition 14
  • Michael Quick, a former provost at USC who left that post in 2019 to return to teaching. The Los Angeles Times wrote, "As the university’s top academic officer, Quick handled many of the complaints against former medical school Dean Carmen Puliafito, who The Times revealed used drugs and partied with criminals during his tenure. Quick reprimanded the dean and ultimately forced him to step down in 2016." 
Puliafito was once a member of the CIRM governing board. USC has received more than $114 million in CIRM awards.

Below is the text of state law concerning the CFAOC and the scope of its authority, which does not include an evaluation of its scientific performance. 
"There shall be a Citizen's Financial Accountability Oversight Committee chaired by the Controller. This committee shall review the annual financial audit, the Controller's report and evaluation of that audit, the financial practices of the institute. The Controller, the Treasurer, the President pro Tempore of the Senate, the Speaker of the Assembly, and the Chairperson of the ICOC shall each appoint a public member of the committee. Committee members shall have medical or patient advocacy backgrounds and knowledge of relevant financial matters. The committee shall provide recommendations on the institute's financial practices and performance. The Controller shall provide staff support. The committee shall hold a public meeting, with appropriate notice, and with a formal public comment
period. The committee shall evaluate public comments and include appropriate summaries in its annual report. The ICOC shall provide funds for all costs associated with the per diem expenses of the committee members and for publication of the annual report."

Monday, November 16, 2020

California's $5.5 Billion Stem Cell Boost: The Journal Nature Reports on "Split" Views, Conflicts and Priorities

The internationally respected journal Nature today took a look at the $5.5 billion refinancing of California's stem cell research program in an article that is not likely to please its supporters. The headline on the piece said:

"California's vote to revive controversial stem-cell institute sparks debate

"The California Institute for Regenerative Medicine will receive billions in state funding — but some scientists oppose the plan."

The first paragraph of the article said, "(S)cientists are split over whether the California Institute for Regenerative Medicine (CIRM) in Oakland is a worthwhile investment for the US state — or for the field of stem-cell research."

In significant ways, the article by senior reporter Nidhi Subbaraman echoed important elements of an examination of CIRM that Nature published in 2008. The journal, in fact, warned at the time of "cronyism" at the agency. (See Nature's editorial here and the article by Erika Check Hayden here.)

Today's latest article in Nature said,

"(C)ritics of CIRM are concerned about oversight at the state agency, which has faced complaints about potential conflicts of interest among its board members for years. They also point out that the field has grown and now receives federal support, making state funding hard to justify — especially amid a pandemic that has imperiled California’s economy."
Comments about priorities and the failure of the $5.5 billion measure (Proposition 14) to correct governance flaws at CIRM were also carried by Nature. Subbaraman wrote,
"'Unfortunately, Proposition 14 sets a bad example for the use of public money for the advancement of science,' says Zach Hall, a neurobiologist who led CIRM as its first president between 2005 and 2007."

Nature continued,

"'You could argue that California would do better, economically and scientifically, to have a CRISPR institute,' Hall says, arguing that the revolutionary precision gene-editing tool is better placed to benefit from such a huge infusion of cash."

 Subbaraman quoted another former top level scientist at CIRM.

"'As scientists, everybody always welcomes additional funding,' says Arlene Chiu, former director of scientific activities at CIRM. 'But as a Californian, one wonders if there are better ways to do this.'"

Nature mentioned a $700,000 study of the agency by the Institute of Medicine in 2012, which recommended a major restructuring of CIRM along with steps to deal with its conflicts of interest, which the IOM regarded as a serious problem. 

The California Stem Cell Report, which has followed the agency since 2005, has analyzed CIRM's awards and reported earlier this year that 79 percent ($2.1 billion) has gone to institutions with links to members of CIRM's governing board. Members of the board cannot vote on grants to their institutions, but they control the direction of the agency and approve plans for all award rounds.

Most of the recommendations by the IOM were not implemented by CIRM or Proposition 14. Nature interviewed one of the members, Cato Laurencin, of the IOM panel that spent months examining CIRM, which financed the study.

Subbaraman wrote,

"'It is very exciting that Prop. 14 passed and that CIRM will continue its funding,' says Cato Laurencin, a biomedical engineer at the University of Connecticut in Farmington, who is not funded by the institute. 'This field is at a bit of an inflection point in terms of our understanding of stem-cell science.'"

Subbaraman's piece included comments from Robert Klein, the real estate developer who sponsored Proposition 14 and poured millions into the campaign for it. Klein was also responsible for writing the 17,000-word measure.

The Nature article said,

"Responding to the criticisms, Klein says he crafted the proposal with the guidance of multiple groups of experts, and kept the mandate deliberately broad to allow for flexibility as the field grows. 'There's an intent here,' he says, 'to have the agency be responsive to the development of science.'"

Friday, November 13, 2020

The AP Says Prop. 14 -- the $5.5 Billion California Stem Cell Measure -- Wins Approval

Robert Klein, sponsor of Proposition 14
California Stem Cell Report photo

California voters have bailed out the "nearly broke" state stem cell agency by approving $5.5 billion more for the 16-year-old program, The Associated Press has declared. 

The AP yesterday called the election on Proposition 14 with 51 percent approval of the measure. This morning, state election officials said the figure still stood at 51 percent (8,025,624) with 49 percent against (7,700,870). An estimated 1,054,820 ballots remain to be counted. 

AP reporter John Rodgers  described the agency as "nearly broke." He wrote that the approval was the narrowest margin of any proposition on the ballot. The result was also a far cry from the 59 percent vote for creation of the agency in 2004. 

At the time, the stem cell program was provided with $3 billion, but the money was nearly gone by this year. The agency was scheduled to begin closing its doors this winter without additional funding. 

The campaign of 2004 raised high expectations among voters that miraculous stem cell cures were just around the corner. However, the agency has yet to help finance a stem cell treatment that is widely available to the general public, although it is helping to finance 64 clinical trials. 

CIRM Chairman Jonathan Thomas said in a statement (full text below) that the agency was "thrilled" by the election result which he said showed that the people of California "recognized our historic achievements."

The official sponsor of Proposition 14 is Robert Klein, a Palo Alto real estate developer. He directed the writing of the 17,000-word proposal as well as directing  the campaign and contributing millions of dollars to the effort. Klein served an identical role in 2004 and became the first chairman of the agency as a result of language that he wrote into the 2004 proposition. 

It is unclear what role, if any, Klein will have at the agency in the next several years. Thomas' term is not set to expire until Dec. 13, 2022.

In a statement, Klein said, 

"The success of Propositon 14 sends a clear message from California voters that one of the most important investments our state can make is in the future health of our families." (full text below) 

Ironically, while Proposition 14 provided for $5 billion-plus in "new," borrowed money (state bonds), it does not provide any funding beyond that amount for the California Institute for Regenerative Medicine (CIRM), as the agency is formally known. That means that CIRM will need another bond measure in 10 to 15 years unless it can devise a plan for financial sustainability, a task that it has failed at over the last 16 years. 

Proposition 14 also significantly expands the scope of the research that CIRM can support and increases the much-criticized size of its governing board from 29 to 35. And it provides a mechanism to hire substantially more employees. 

CIRM's staffing peaked at about 56 and stood at 33 at last report. It will need to begin hiring more soon if it is to ramp up its award program to levels of previous years.

The CIRM board is scheduled to meet next month when it may take up revisions in its strategic plan and other forward-looking matters. 

Here is the full statement from Thomas, chairman of the CIRM governing board: 

“We are thrilled to see Proposition 14  approved by the voters of California. We are proud of what we have achieved so far - the cures and therapies we helped develop, the billions we brought into the state in additional investments, and the tens of thousands of jobs we created – and we look forward to continuing that work.


"We are honored by the trust the people of California have placed in us, and by the support of our extraordinary patient advocate community and by the many Chambers of Commerce around California who have all recognized our historic achievements.


"We are already working on ways to repay that trust and bring stem cell and regenerative therapies to all the people of this great state, particularly for communities that have traditionally been overlooked or underserved.” 

Here is Klein's statement from the campaign website:

“The success of Prop. 14 sends a clear message from California voters that one of the most important investments our state can make is in the future health of our families. Over the past decade, California has made incredibly thoughtful and impactful investments in developing stem cell therapies and cures for diseases and conditions like diabetes, cancer, blindness, Parkinson’s, paralysis and many more; now we know this progress and work to mitigate human suffering, restore health and improve the human condition will continue,” said Robert and Danielle Klein, Chairs of Californians for Stem Cell Research, Treatments and Cures.
“A special thank you to California’s voters and our supporters in passing this critical measure. Today would not have been possible without our historically unprecedented coalition of patient advocate organizations and individuals – the heart and soul of this campaign – who worked tirelessly to overcome all obstacles and help secure a victory for patients and their families, and deliver hope to those searching for a cure for generations to come.”

“YES on Proposition 14 was outspent by a majority of the other measures on the ballot, but from day one, our mission has been too important to give up. Patients and their families looking for cures and treatments for their loved ones do not understand the meaning of impossible, and neither did the YES on Prop. 14 campaign. This measure would not have overcome these challenges without the patient advocacy community that refused to take no for an answer and continued to fight for their loved ones; patient advocates, along with the empathy, foresight and continuing commitment of California voters, have delivered a victory for YES on Proposition 14 and secured funding to improve or save the lives of millions.”

Thursday, November 12, 2020

$5.5 Billion California Stem Cell Measure Holding Steady for Approval; Stem Cell Agency Set Today to Give Away $24 Million

 As directors of the $3 billion California stem cell agency are scheduled to meet later this morning, narrow voter approval of a ballot measure aimed at saving the agency's financial life is nearing a conclusion. 

The latest count by state election officials  at 8:18 a.m. PDT today continues to show Proposition 14 holding steady with 51.1 percent of the vote, a figure that has been virtually unchanged since last week. The percentage translates to 7.9 million votes. 

Negative votes are running at 48.9 percent or 7.6 million. State election officials are estimating that "unprocessed" ballots are running at 1.5 million. The figure is the latest from the state. H however, it is old, dating back to Tuesday at 6 p.m. PDT.

The agency is running out of the $3 billion originally provided by voters in 2004. Proposition 14 would provide the agency with $5.5 billion more over the next 10 to 15 years and make major changes in the agency, including a significant expansion in what it can fund.  The money would be borrowed by the state. No provision for funding the agency is provided after the money runs out again. 

The new ballot measure will not go into effect until after it is officially certified, which may not happen for another 28 days.

The meeting of the stem cell agency's board begins at 10 a.m. PDT today and is open to the public, including questions. Its agenda includes the award of as much as $21.7 million in clinical level grants and $2.5 million for basic research.  Several researchers have sent letters to the board appealing rejection of their applications by reviewers, who make the de facto decisions on the awards.

The meeting agenda also includes a proposal involving a possible loan to Viacyte, Inc., of San Diego. The agency has already pumped $52 million into the firm. Information on the meeting agenda concerning the loan is a bit laconic. The California Stem Cell Report has queried the agency for more details. 

Tuesday, November 10, 2020

Latest Prop. 14 Count: 51.1 Percent Yes, 48.9 Percent No

As of 7:05 a.m. PDT today, the count for Proposition 14, the $5.5 billion California stem cell measure, stands at 51.1 percent for and 48.9 percent against. It is not clear when election officials will stop counting, but certification is required within 30 days.  An estimated 2.7 million votes remain to be counted, according to election officials. 

Monday, November 09, 2020

Vote Margin Tightens on California Stem Cell Measure

California Secretary of State graphic

The margin of approval for California's $5.5 billion stem cell ballot measure has narrowed very slightly with the latest figures showing 51 percent of voters in favor, down from 51.1 percent last week. 

The "semi-official" vote count at 9:08 a.m today from the Secretary of State's office tallied 7,085,881 (51.0 percent) in favor of Proposition 14 and 6,802,604 against (49 percent). State election officials, however, did not have a count for the number of all outstanding ballots, as of last night.

The total number of ballots reported cast at this point is about 13.9 million. About 22 million persons are registered to vote. A significant percentage of those are not expected to have voted at all. Many vote only on races important to them, such as the presidential contest. Still others simply don't work their way through the ballot to the propositions. 

Some readers may ask: Is it a possibility that Proposition 14 could ultimately lose in the official, certified count that is not due until December? The answer is the usual one for questions of possibilities: Anything is a possibility. 

However, at this stage in the count, it is more likely than not that the remaining outstanding votes will break in the pattern already established, with Proposition 14 being approved.  But, as noted, anything is possible.

Regarding the map below, it is a static version of the one on the Secretary of State's site. Red indicates counties that did not support Proposition 14. If you click on this sentence, the link will take you to an interactive version that opens up each county.  

Wednesday, November 04, 2020

Prop. 14 Campaign Says Race Still Too Close to Raise Victory Flag for $5.5 Billion Measure

California voters have apparently approved spending $5.5 billion more on stem cell research over the next 10 to 15 years and significantly broadening the scope of its state stem cell agency, according to unofficial figures this morning. 

The refinancing of the agency, officially known as the California Institute for Regenerative Medicine (CIRM), was approved by 51.1 percent of the voters compared to 48.9 percent against, with 99 percent of the votes in, state election officials reported. 

(However, a spokeswoman for the Proposition 14 campaign said following publication of this item that the vote is too close to call. "There are at least 4 or 5 million votes that still need to be counted, she said.) 

CIRM was created by voters in 2004 who also provided it with $3 billion in borrowed money. However, the cash began to run out last year, and staffers were leaving. The Oakland-based agency was planning to begin closing its doors this winter in the event that Proposition 14 was not approved. 

Approval of Proposition 14 means the revival of an enterprise that is unique in California history and in the nation. No other state has mounted a stem cell program on the scale of CIRM. Voters 16 years ago endorsed it with 59 percent of the vote following a campaign that raised optimistic expectations that stem cell cures were right around the corner. 

However, CIRM has not financed a stem cell therapy that is widely available to the general public. It is helping, however, to finance 64 clinical trials.  

In addition to providing $5.5 billion in state bonds, Proposition 14 authorizes CIRM to expand its operations into such areas as mental health, therapy delivery and "aging as a pathology." Its 29-member board will be expanded to 35, raising the likelihood of more conflicts of interests involving the board. 

An analysis this summer by the California Stem Cell Report showed that 79 percent of the agency's awards have gone to institutions with links to members of the CIRM board. The board members cannot vote on awards to their specific institutions. But they vote on and can change award "concept" programs that can benefit their institutions. 

In 2012, a $700,000 evaluation of CIRM, commissioned by the agency itself, recommended a major restructuring of CIRM and was critical of the conflict of interest issues posed by its structure. Proposition 14 does little to address those recommendations from the prestigious Insitute of Medicine

The 2004 ballot initiative also deliberately structured CIRM to avoid oversight by the governor and legislature. Funds flow directly to CIRM without requiring legislative approval. 

The immediate task now facing the agency is to adopt a new strategic plan for spending the $5.5 billion and hiring additional staff. The number of its employees dwindled to 33 this summer, down from a high of 56. 

The CIRM board yesterday scheduled a public, online meeting for Nov. 12. Its agenda currently does not include approval of the new strategic plan that its CEO Maria Millan and CIRM staff have been devising. 

Proposition 14 also could mean the removal of some board members whose terms are 50 percent expired. But that would depend on the pleasure of the appointing authorities. 

Tuesday, November 03, 2020

Prop. 14 Ballot Results: Narrow Lead for the $5.5 Billion Measure

Proposition 14, the $5.5 billion California stem cell measure, is winning approval from about 52 percent of voters with slightly over half of the state's precincts reporting. 

But the margin is too small to declare a win for supporters of the measure. Look for an update on the vote early tomorrow morning (Wednesday). 

Voting on Proposition 14

(10:25 p.m. PDT)

Geographic Area

Percentage Yes

Percentage No

Percentage of Precincts Reporting 





Los Angeles County




San Diego




Orange County




Riverside County




San Bernardino




Election Results Prop. 14: Returns are Mixed and Very Preliminary

Early returns on voting on Proposition 14, the $5.5 billion California stem cell measure, are mixed and too preliminary to make firm conclusions about its fate. The counties listed are the five most populous in the state. Polls closed at 8 p.m. PDT.

These early returns do not necessarily indicate the final result, which may not be known for days, depending on how close the margin is.

Voting on Proposition 14

Geographic Area

Percentage Yes

Percentage No

Percentage of Precincts Reporting 





Los Angeles County




San Diego




Orange County




Riverside County




San Bernardino




Prop. 14 Narrrowly Leading in Extremely Early Returns

Voting on Proposition 14

Early returns on voting on Proposition 14, the $5.5 billion California stem cell measure, showed that the measure was running ahead with  the state's voter. The counties listed are the five most populous in the state. Polls closed at 8 p.m. PDT.

These early returns do not necessarily indicate the final result, which may not be known for days, depending on how close the margin is. 







of Precincts



Los Angeles County


San Diego


Orange County


Riverside County


San Bernardino


Search This Blog